Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people notice Mounjaro's appetite-reducing effects within the first one to four weeks of starting treatment, though meaningful weight change typically becomes visible over two to three months. The medicine works from the first dose, but the body's response builds gradually — and the timeline differs by dose, individual metabolism, and lifestyle factors. Mounjaro is a prescription-only medicine, and a GPhC-registered prescriber assesses clinical suitability before any treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The starter dose of 2.5 mg is designed with one purpose in mind: letting your digestive system settle before any therapeutic weight-loss effect is expected. Its job is adjustment, not rapid change. Many people do notice that their appetite feels slightly different quite early (a full feeling arriving sooner at meals, or less interest in snacking) but weight on the scales tends to shift modestly at this stage.
Nausea, some loose stools, or mild indigestion are common in these opening weeks. They are a predictable response to a medicine that slows gastric emptying and acts on gut hormone receptors; for most people they settle within a fortnight. Staying well hydrated and eating smaller portions helps considerably. The NHS tirzepatide patient page sets out the side-effect profile clearly and is worth reading before you start.
A practical note: if your first prescription arrives just before a bank holiday or a week when your routine is already disrupted, that is still a perfectly reasonable time to begin. Dose timing on injection day matters more than the calendar date.
After four weeks at 2.5 mg, most prescribers move patients to 5 mg if tolerated. This is the point where many people begin to feel the treatment working more noticeably: hunger between meals reduces more reliably, portion sizes feel naturally smaller, and the scales start to move with more consistency.
Weight loss in this window is real but rarely dramatic. A steady one to two pounds a week is a healthy pace and reflects genuine fat loss rather than water shifts. The SURMOUNT-1 trial, published in the New England Journal of Medicine, involved thousands of adults and tracked results across 72 weeks, not 12. That context matters: expecting dramatic change at week six sets up disappointment that the data simply does not support.
If you want to understand how tirzepatide compares to semaglutide at this stage of treatment, our page on tirzepatide's timeline covers the mechanism and head-to-head evidence in more detail.
This is the stretch most people describe as when Mounjaro truly starts to feel like it is working. Appetite suppression is steadier, the dose is higher (often 7.5 mg or above, depending on tolerability and the prescriber's clinical judgement), and cumulative weight loss becomes noticeable to others as well as yourself.
Body composition shifts during this period too. Muscle mass can fall alongside fat if protein intake is low and activity levels drop, something worth raising with your prescriber. The NHS England wraparound care guidance specifically highlights diet quality and activity as part of supported treatment for exactly this reason.
Patience here is not passive. People who track what they eat, keep moving, and maintain open contact with their clinical team tend to report the clearest progress. Understanding the full cost picture of sustained private treatment can also help with planning; our Mounjaro cost page sets out what to expect from the market as a whole.
The SURMOUNT-1 data shows that weight loss continues accumulating well beyond six months at the highest tolerated dose, with the 72-week average reaching around 20–21% body weight at 15 mg. That figure (often cited in headlines) represents roughly a year and a half of consistent treatment, not a six-week sprint.
A question our prescribers hear regularly: what if nothing seems to be happening? Slow response in the early months does not necessarily predict the outcome at month nine. Dose, adherence, dietary habits, and individual biology all interact. NICE's appraisal of tirzepatide, TA1026, notes that continuing treatment should be reviewed if less than 5% weight loss has occurred after six months at the highest tolerated dose, a clinical decision made with your prescriber, never unilaterally.
If you have questions about how the dose schedule affects your personal timeline, this related page on Mounjaro's working time addresses that in more depth. Readers who want a more detailed look at how long before Mounjaro starts working at each dose stage, including what the clinical evidence says about early versus later responses, will find that covered there too. For a clearer picture of how long till Mounjaro starts working in practical, week-by-week terms, that page walks through the timeline in straightforward language. And for a broader look at what the treatment journey involves, our Mounjaro overview is the starting point.
When you are ready to talk through your individual situation with a real clinician, start your free consultation and a GPhC-registered prescriber will review your case the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.